Fundraising Fox
/People
Sign in

Eric Linsley

Investor

Managing Partner at BioInnovation Capital · Board director at Cereius · Executive at Envisia Therapeutics

Durham, North Carolina

Writes $100K – $5M checks · typically $1.5M

Find your path to Eric

247 people in our graph can introduce you to Eric.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Ed Field to introduce you to Eric

You →Ed · together at BioLabs North Carolina (2017–2026) →Eric

Ask Jamie Chen to introduce you to Eric

You →Jamie · 3 people · together at Envisia Therapeutics →Eric

Ask Sam Okafor to introduce you to Eric

You →Sam · 8 people · together at McKinsey & Company →Eric

Sign up to find every way you can get introduced to Eric

  • Your email: the people you already email who know Eric
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Eric
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

Eric Linsley is Managing General Partner at BioInnovation Capital, where he oversees fund operations, manages the North Carolina laboratory, and invests in therapeutics, laboratory tools, diagnostics, and devices. He previously spent over two decades at Pappas Ventures in Durham, North Carolina, where he sourced and managed investments in numerous life sciences companies, including Peninsula Pharmaceuticals (acquired by Johnson & Johnson), Cerexa (acquired by Forest Laboratories), and public companies such as LipoScience, Liquidia, and Ultragenyx. Prior to Pappas Ventures, he served as Chief Financial Officer of AutoCyte and TriPath Imaging, a medical device company acquired by Becton Dickinson in 2006.

Board director at Cereius

Intro paths

→

In turn, Eric can intro founders to Cereius's investors below.

Cereius's investors · 2

BioInnovation CapitalCambridge · since 2018Mission BiocapitalSan Francisco · $500K checks · since 2018

Executive at Envisia Therapeutics

Intro paths

→

In turn, Eric can intro founders to Envisia Therapeutics's investors below.

Envisia Therapeutics's investors · 7

+ND CapitalWoodside · $540K – $5.4M checksARCH Venture PartnersChicago · $50K – $250M checksCanaan PartnersStamford · $500K – $20M checks · since 2015Illumina VenturesFoster CityNew Enterprise Associates (NEA)Menlo Park · $200K – $40M checks · since 2015OMX VenturesLincolnshirePappas CapitalDurham

Experience

  1. BioInnovation CapitalManaging General Partnercurrent2017 — presentRaleigh-Durham, North Carolina Area
  2. BioLabs North CarolinaCo-Foundercurrent2016 — presentRaleigh-Durham, North Carolina Area
  3. Envisia TherapeuticsChief Financial Officer2015 — 2017Raleigh-Durham, North Carolina Area
  4. VariousLife Science Venture Capitalist2000 — 2014Raleigh-Durham, North Carolina Area
  5. TriPath ImagingCFO, VP Operations1997 — 2000Burlington, NC
  6. Ampersand VenturesPartner1994 — 1997Wellesley, MA
  7. Ampersand VenturesAssociate1991 — 1994Wellesley, MA
  8. Bain & CompanyConsultant1989 — 1991Greater Boston Area
  9. McKinsey & CompanyConsultant1988Greater New York City Area
  10. Arthur AndersenCPA1985 — 1987

Skills & more

Strategic Planning1Strategy2Business Strategy4Mergers4Start-ups14Corporate Development11Due Diligence9Venture Capital26Valuation2Mergers & Acquisitions15Commercialization4Drug Development2
+12 moreIntellectual PropertyBusiness DevelopmentClinical DevelopmentEntrepreneurshipBiotechnologyTechnology TransferLicensingVenture FinancingStrategic PartnershipsProduct DevelopmentPharmaceutical IndustryHealthcare

From Eric's professional profile.

Deals · 1

CereiusBoard seat

via BioInnovation Capital · filed Aug 2018 · $6M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Sources: SEC Form D filings · curated public sources.

Network3

Debra K. Liebert
Investor at Domain Associates
Ravi Viswanathan
Founder and Managing Partner at NewView Capital
Stephen Bloch
General Partner at Canaan Partners

Investors connected to Eric in public investor directories — a warm-intro map.

Frequently asked questions

Who is Eric Linsley?
Eric Linsley is Managing General Partner at BioInnovation Capital, where he oversees fund operations, manages the North Carolina laboratory, and invests in therapeutics, laboratory tools, diagnostics, and devices. He previously spent over two decades at Pappas Ventures in Durham, North Carolina, where he sourced and managed investments in numerous life sciences companies, including Peninsula Pharmaceuticals (acquired by Johnson & Johnson), Cerexa (acquired by Forest Laboratories), and public companies such as LipoScience, Liquidia, and Ultragenyx. Prior to Pappas Ventures, he served as Chief Financial Officer of AutoCyte and TriPath Imaging, a medical device company acquired by Becton Dickinson in 2006.
Where does Eric Linsley work?
Eric Linsley is Managing Partner at BioInnovation Capital and Board director at Cereius and Executive at Envisia Therapeutics.
What check size does Eric Linsley write?
Eric Linsley typically writes checks of $100K – $5M.
What boards does Eric Linsley sit on?
Eric Linsley holds tracked board seats at Cereius.
What companies has Eric Linsley invested in?
Investments tracked here include Barosense, Cereius, Liquidia Technologies, Milestone Pharmaceuticals.
Where did Eric Linsley go to school?
Eric Linsley studied at The Wharton School (MBA, Marketing); New York University (Master of Science - MS, Accounting); Trinity College-Hartford (Bachelor of Science - BS, Economics).

Same school

Shared employers

Also worked at BioLabs North Carolina1

Ed FieldGeneral Partner at Cape Fear BioCapital

Also worked at Envisia Therapeutics1

Christy ShafferDirector at Trefoil Therapeutics